Generate Biomedicines (NASDAQ:GENB) Shares Down 8.5% – Here’s Why

Generate Biomedicines Inc (NASDAQ:GENB)’s share price was down 8.5% during mid-day trading on Friday . The stock traded as low as $14.71 and last traded at $14.38. 86,802 shares traded hands during mid-day trading, a decline of 88% from the average daily volume of 701,000 shares. The stock had previously closed at $15.72.

Analysts Set New Price Targets

Several research firms have weighed in on GENB. Morgan Stanley lifted their target price on Generate Biomedicines from $20.00 to $22.00 and gave the company an “overweight” rating in a research note on Thursday, May 14th. HC Wainwright boosted their price objective on shares of Generate Biomedicines from $16.00 to $25.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Wall Street Zen lowered shares of Generate Biomedicines from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Cantor Fitzgerald assumed coverage on shares of Generate Biomedicines in a research note on Tuesday, March 24th. They set an “overweight” rating for the company. Finally, Zacks Research upgraded shares of Generate Biomedicines to a “hold” rating in a report on Wednesday, March 25th. Six equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $25.40.

Generate Biomedicines Stock Performance

The firm has a market cap of $1.83 billion and a P/E ratio of -13.32. The firm has a 50 day simple moving average of $14.49.

Generate Biomedicines (NASDAQ:GENB) last released its quarterly earnings data on Thursday, May 7th. The company reported ($1.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.59).

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.